

## List of Tables

| <b>Sr. No:</b> | <b>Table No.</b> | <b>Table title</b>   | <b>Page No.</b> |
|----------------|------------------|--|-----------------|
| 1              | 2.1              | Potential MMP inhibitors   | 34              |
| 2              | 4.1              | Socio-demographic details of the subjects  | 45              |
| 3              | 4.2              | Clinical details of oral cancer patients   | 46              |
| 4              | 4.3              | Methodologies employed for analysis of parameters  | 48              |
| 5              | 4.4              | Primer sequence and amplicon size of genes   | 65              |
| 6              | 4.5              | Reaction conditions for RT-PCR analysis  | 66              |
| 7              | 5.1              | Significance of expression levels of 192 kDa, 170 kDa, 116 kDa and 44 kDa glycoprotein in TNH and TH Controls with TNH and TH oral cancer patients | 78              |
| 8              | 5.2              | Comparison of serum and salivary TSA/TP ratio between TNH and TH groups of subjects  | 84              |
| 9              | 5.3              | Comparison of serum and salivary TSA/TP ratio according to stage of the disease and metastasis   | 86              |
| 10             | 5.4              | ROC curve analysis for serum and salivary TSA/TP ratio   | 87              |
| 11             | 5.5              | Survival analysis of serum and salivary TSA/TP ratio   | 88              |
| 12             | 5.6              | Serum and salivary sialidase activity in metastasis and various stages of disease  | 90              |
| 13             | 5.7              | ROC curve analysis for serum and salivary sialidase activity   | 91              |
| 14             | 5.8              | Kaplan Meir's survival analysis of serum and salivary sialidase activities with ROC cut-off  | 92              |
| 15             | 5.9              | Serum and salivary $\alpha$ -2,3 and $\alpha$ -2,6 sialoproteins in various stages and metastasis  | 95              |
| 16             | 5.10             | ROC curve analysis for serum and salivary $\alpha$ -2,3 and $\alpha$ -2,6 sialoproteins  | 97              |
| 17             | 5.11             | Serum and salivary $\alpha$ -2,3 and $\alpha$ -2,6 ST activities with clinico-pathological parameters  | 100             |
| 18             | 5.12             | ROC curve analysis for serum and salivary $\alpha$ -2,3 ST and $\alpha$ -2,6 ST  | 100             |
| 19             | 5.13             | Significance of serum and salivary $\alpha$ -2,3 and $\alpha$ -2,6 ST in distinguishing PT vs. CR and PT vs. NR                                    | 101             |
| 20             | 5.14             | Survival analysis of serum and salivary $\alpha$ -2,3 and $\alpha$ -2,6 ST with ROC cut-off  | 102             |
| 21             | 5.15             | Pearson's correlation analysis between serum sialylation changes   | 103             |
| 22             | 5.16             | Pearson's correlation analysis between salivary sialylation changes  | 103             |
| 23             | 5.17             | ROC curve analysis for serum and salivary fucoproteins   | 107             |
| 24             | 5.18             | Serum and salivary $\alpha$ -L-fucosidase activity in TNH and TH subgroups   | 109             |
| 25             | 5.19             | Comparison of Serum and salivary $\alpha$ -L-fucosidase activity according to stage and metastasis   | 110             |
| 26             | 5.20             | ROC curve analysis for serum and salivary $\alpha$ -L-fucosidase activity  | 111             |

|    |      |   |     |
|----|------|---|-----|
| 27 | 5.21 | Survival analysis of serum and salivary $\alpha$ -L-fucosidase activity with ROC cut-off  | 112 |
| 28 | 5.22 | ROC curve analysis of the transcripts showing cut-off, sensitivity, specificity, and AUC  | 117 |
| 29 | 5.23 | Multivariate analysis of <i>ST3GAL1</i> , <i>FUT3</i> , <i>FUT5</i> and <i>FUT6</i> transcripts with clinico-pathological parameters        | 120 |
| 30 | 5.24 | Comparison of pro, active and total MMP-2 and MMP-9 in controls, patients with OPC and oral cancer patients. p values by student's 't' test | 124 |
| 31 | 5.25 | Correlation analysis between different forms of MMP-2 and MMP-9   | 124 |
| 32 | 5.26 | Multivariate analysis of different forms of plasma MMP-2 and MMP-9 with various clinic-pathological parameters                              | 126 |
| 33 | 5.27 | ROC curve analysis of plasma pro, active and total MMP-2 and MMP-9  | 127 |
| 34 | 5.28 | Survival analysis of different forms of plasma MMPs using ROC cut-off   | 128 |
| 35 | 5.29 | Correlation analysis between all forms of salivary MMPs   | 131 |
| 36 | 5.30 | ROC curve analysis of salivary pro MMP-9, active MMP-9 and truncated 42 kDa MMP   | 132 |
| 37 | 5.31 | Survival analysis of different forms of salivary MMPs using ROC cut-off   | 132 |
| 38 | 5.32 | Survival analysis of truncated E-cadherin protein and <i>ECAD</i> mRNA  | 135 |
| 39 | 5.33 | <i>CJUN</i> mRNA expression with reference to stage and metastasis  | 137 |
| 40 | 5.34 | Survival analysis of <i>CJUN</i> mRNA and protein with ROC cut-off  | 139 |
| 41 | 5.35 | Pearson's correlation between plasma MMPs and serum glycosylation changes   | 144 |
| 42 | 5.36 | Pearson's correlation between salivary MMPs and salivary glycosylation changes  | 145 |
| 43 | 5.37 | Pearson's correlation between glycosylation, <i>ECAD</i> mRNA and protein, <i>CJUN</i> mRNA and protein                                     | 146 |
| 44 | 5.38 | Pearson's correlation between E-cadherin protein and mRNA, <i>CJUN</i> mRNA and Protein   | 146 |
| 45 | 5.39 | Correlation analysis of plasma and salivary MMPs with E-cadherin and c-Jun protein and mRNA   | 147 |
| 46 | 5.40 | Correlation between pEGFR, truncated E-cadherin protein, plasma MMPs and c-Jun  | 148 |